Catch and Release Immunotoxins: CAR-Bombs for Cancer
捕获并释放免疫毒素:治疗癌症的 CAR 炸弹
基本信息
- 批准号:10062878
- 负责人:
- 金额:$ 36.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-12-07 至 2021-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAmerican Cancer SocietyAntibodiesBindingBiologicalCarcinoembryonic AntigenCell surfaceCellsCessation of lifeColorectal CancerCytoplasmDataDiagnosisDissociationDoseDrug KineticsEndosomesEvaluationExhibitsGALAHealthHumanImmunotoxinsIn VitroIncidenceIndividualInvestigationKineticsLiposomesMalignant NeoplasmsMembraneModelingMonoclonal AntibodiesMusOperative Surgical ProceduresPatternPeptidesPhysiologicalPlasmaPopulationProteinsRadiationRibosomesSafetySmall Interfering RNASumSystemTestingToxic effectToxinToxin ConjugatesTumor SuppressionUnited StatesWorkanaloganti-cancerantibody conjugateantigen bindingbasecancer cellcancer therapycancer typecellular targetingchemotherapycytotoxicityhuman modelimprovedin vivomacromoleculemembrane modelmouse modelneoplastic cellnovelpharmacokinetic modelreceptor bindingreceptor mediated endocytosistargeted deliverytumortumor growthtumor xenograftuptakevirtualvirtual delivery
项目摘要
Abstract
The American Cancer Society estimates that in 2016 there will be 1.7 million new cancer cases diagnosed and
600,000 cancer deaths in the United States. Although advances have been made in the treatment of cancer
with surgery, radiation, chemotherapy, and with biologics, there is a critical need to develop novel treatment
approaches with promise for improved selectivity, potency, and efficacy. This project introduces a new and
previously untested platform strategy to enhance the efficiency of delivery of macromolecules to the cytoplasm
of targeted cells. The central component of the strategy is the use of “catch-and-release” monoclonal
antibodies (CAR), with pH-dependent receptor binding. The CAR antibodies are conjugated to highly potent
macromolecular toxins (CAR-toxin) and to endosome escape peptides (CAR-EEP). Combined administration
of CAR-toxin and CAR-EEP conjugates allows efficient, targeted delivery and release of the toxin in the
cytoplasm, enabling highly selective and potent anti-cancer efficacy. To pursue this project, we have
developed a novel catch-and-release anti-carcinoembryonic antigen (CEA) antibody (10H6), with high affinity
CEA binding at physiological pH, and with dramatically reduced binding at acidic pH. Preliminary data have
been generated to assess the binding, cytotoxicity, and pharmacokinetics of 10H6, which in sum, strongly
support the feasibility of the work. An interdisciplinary team has been assembled to evaluate this approach,
with three experimental aims that will: (1) examine and optimize the utility of catch and release conjugates for
cytoplasmic delivery of macromolecules to cancer cells in vitro, (2) test hypotheses regarding the tumor
selectivity of in vivo disposition of the antibody conjugates, and (3) evaluate the safety and efficacy of the
catch-and-release mAb conjugates in the treatment of mice bearing human xenograft tumors. The project, if
successful, will establish a new targeting concept, with potential utility in enhancing the efficiency of
cytoplasmic delivery of virtually any macromolecule to any type of cancer.
抽象的
美国癌症协会估计,2016 年将有 170 万新诊断癌症病例
尽管美国在癌症治疗方面取得了进展,但仍有 60 万人因癌症死亡。
通过手术、放疗、化疗和生物制剂,迫切需要开发新的治疗方法
该项目引入了一种新的方法,有望提高选择性、效力和功效。
以前未经测试的平台策略,可提高大分子递送至细胞质的效率
该策略的核心部分是使用“捕获并释放”单克隆抗体。
抗体 (CAR),具有 pH 依赖性受体结合能力。 CAR 抗体与高效能的受体结合。
大分子毒素(CAR-毒素)和内体逃逸肽(CAR-EEP)联合给药。
CAR-毒素和 CAR-EEP 缀合物的结合可实现毒素在体内的高效、有针对性的递送和释放
细胞质,实现高度选择性和有效的抗癌功效。
开发出一种新型捕获并释放抗癌胚抗原(CEA)抗体(10H6),具有高亲和力
初步数据显示,CEA 在生理 pH 值下的结合力显着降低。
生成用于评估 10H6 的结合、细胞毒性和药代动力学,总之,强烈
支持该工作的可行性,已经组建了一个跨学科团队来评估这种方法,
具有三个实验目标:(1)检查和优化捕获和释放结合物的效用
体外将大分子通过细胞质递送至癌细胞,(2) 检验有关肿瘤的假设
抗体缀合物的体内处置的选择性,以及(3)评估抗体缀合物的安全性和有效性
捕获并释放单克隆抗体结合物治疗携带人类异种移植肿瘤的小鼠。
成功,将建立一个新的目标概念,具有提高效率的潜在效用
几乎任何大分子的细胞质递送至任何类型的癌症。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier.
- DOI:10.3389/fphar.2022.837744
- 发表时间:2022
- 期刊:
- 影响因子:5.6
- 作者:Bordeau BM;Abuqayyas L;Nguyen TD;Chen P;Balthasar JP
- 通讯作者:Balthasar JP
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors.
- DOI:10.20892/j.issn.2095-3941.2020.0704
- 发表时间:2021-08-15
- 期刊:
- 影响因子:5.5
- 作者:Bordeau BM;Balthasar JP
- 通讯作者:Balthasar JP
Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy.
- DOI:10.1208/s12248-022-00698-x
- 发表时间:2022-03-25
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.
- DOI:10.1158/1535-7163.mct-22-0192
- 发表时间:2022-10-07
- 期刊:
- 影响因子:5.7
- 作者:
- 通讯作者:
Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
基于生理学的结直肠癌异种移植小鼠模型中“捕获并释放”抗癌胚抗原单克隆抗体的药代动力学建模。
- DOI:10.1016/j.xphs.2018.09.037
- 发表时间:2019
- 期刊:
- 影响因子:3.8
- 作者:Polli,JosephRyan;Engler,FrankA;Balthasar,JosephP
- 通讯作者:Balthasar,JosephP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph P Balthasar其他文献
Joseph P Balthasar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph P Balthasar', 18)}}的其他基金
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
急性髓系白血病 ADC 治疗的药代动力学/药效学优化
- 批准号:
10561230 - 财政年份:2023
- 资助金额:
$ 36.42万 - 项目类别:
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
通过反向靶向增强 ADC 选择性:机理研究和优化
- 批准号:
10415220 - 财政年份:2021
- 资助金额:
$ 36.42万 - 项目类别:
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
通过反向靶向增强 ADC 选择性:机理研究和优化
- 批准号:
10312178 - 财政年份:2021
- 资助金额:
$ 36.42万 - 项目类别:
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
通过反向靶向增强 ADC 选择性:机理研究和优化
- 批准号:
10623301 - 财政年份:2021
- 资助金额:
$ 36.42万 - 项目类别:
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors
增加单克隆抗体摄取、分布和治疗实体瘤疗效的药代动力学策略
- 批准号:
10623152 - 财政年份:2020
- 资助金额:
$ 36.42万 - 项目类别:
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors
增加单克隆抗体摄取、分布和治疗实体瘤疗效的药代动力学策略
- 批准号:
10164739 - 财政年份:2020
- 资助金额:
$ 36.42万 - 项目类别:
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors
增加单克隆抗体摄取、分布和治疗实体瘤疗效的药代动力学策略
- 批准号:
10397091 - 财政年份:2020
- 资助金额:
$ 36.42万 - 项目类别:
Pharmacokinetic strategies to optimize IP chemotherapy
优化IP化疗的药代动力学策略
- 批准号:
7144306 - 财政年份:2006
- 资助金额:
$ 36.42万 - 项目类别:
Pharmacokinetic strategies to optimize IP chemotherapy
优化IP化疗的药代动力学策略
- 批准号:
7646274 - 财政年份:2006
- 资助金额:
$ 36.42万 - 项目类别:
Pharmacokinetic strategies to optimize IP chemotherapy
优化IP化疗的药代动力学策略
- 批准号:
7286074 - 财政年份:2006
- 资助金额:
$ 36.42万 - 项目类别:
相似海外基金
Nucleic Acid Nanoparticle-based Monoclonal Antibody Mimics
基于核酸纳米颗粒的单克隆抗体模拟物
- 批准号:
10201231 - 财政年份:2021
- 资助金额:
$ 36.42万 - 项目类别:
Nucleic Acid Nanoparticle-based Monoclonal Antibody Mimics
基于核酸纳米颗粒的单克隆抗体模拟物
- 批准号:
10841112 - 财政年份:2021
- 资助金额:
$ 36.42万 - 项目类别:
Production of a Nanoparticle Vaccine to Aid in Smoking Cessation
生产有助于戒烟的纳米颗粒疫苗
- 批准号:
10194440 - 财政年份:2020
- 资助金额:
$ 36.42万 - 项目类别:
OPN neutralization monoclonal antibody 100G2 for human pancreatic cancer immunotherapy
用于人胰腺癌免疫治疗的 OPN 中和单克隆抗体 100G2
- 批准号:
10009769 - 财政年份:2020
- 资助金额:
$ 36.42万 - 项目类别:
Production of a Nanoparticle Vaccine to Aid in Smoking Cessation
生产有助于戒烟的纳米颗粒疫苗
- 批准号:
10006930 - 财政年份:2020
- 资助金额:
$ 36.42万 - 项目类别: